Cover Image
Market Research Report
Product code 
1064943

Cancer Tumor Profiling Market by Technique, by Technology and by Application - Global Opportunity Analysis and Industry Forecast 2022-2030

Published: | Next Move Strategy Consulting | 592 Pages | Delivery time: 1-2 business days

Price

Back to Top
Cancer Tumor Profiling Market by Technique, by Technology and by Application - Global Opportunity Analysis and Industry Forecast 2022-2030
Published: March 1, 2022
Next Move Strategy Consulting
Content info: 592 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents

Market Definition:

The Cancer Tumor Profiling Market size was valued at USD 12.98 billion in 2022 and is predicted to reach USD 31.67 billion by 2030 with a CAGR of 11.8% from 2022-2030. Cancer profiling or the tumor profiling is a laboratory test conducted to identify certain genes or the gene mutations, proteins, or other biomarkers in a sample of tumor tissue. Tumor profiling can aid in treatment planning and predicting if cancer will return or spread to other places of the body. Cancer profiling is not only effective in the molecular profiling of common malignancies like lymphoma and breast cancer, but also in the molecular profiling of lung cancer, prostate cancer, and acute leukaemia. Cancer profiling has become more important in molecular diagnosis, since a better knowledge of cancer tumor allows clinicians to make more informed therapeutic decisions and prevent "over-treating" cancer patients.

Market Dynamics and Trends

Growing prevalence of cancer globally and increasing adoption of precision medicine options are pacing new paths for the advanced diagnostic products for determination of the cancerous gene and targeted therapies for the identical.

According to the International Agency for Research on Cancer, 1 in 5 people develop cancer during their lifetime across globe. Also, 1 in 8 men and 1 in 11 women die from the disease indicating significant need for effective diagnostic and therapeutic options. In addition, increasing new cancer cases owing to ageing population and lifestyle changes are likely to drive the demand for cancer profiling products in the coming years.

Moreover, new estimates from GLOBOCAN suggests that quite 50 million people live within five years of past cancer diagnosis. Factors such as increased research and development activities and new product approvals are expected to enhance the market growth. Furthermore, enormous sums of money are raised for the development of cancer-fighting products. According to a study published by ecancer-medicalscience, roughly 153 public research funding organizations (RFO) in the EU and the United States spent more than €1 million on oncology each year. RFOs in the EU spent a total of €2.79 billion, while RFOs in the US spent a total of €5.8 billion.

However, the high cost of cancer profiling tests, as well as a lack of access to the healthcare infrastructure required for cancer profiling, are limiting the market's expansion over the forecast period. Tumor profiling tests are cutting-edge, and they function by identifying tumor mutations and establishing a therapy pathway tailored to the patient's needs. Due to the exorbitant cost of these tests, which are such a sophisticated technology, they are only used by a small percentage of the population in economically depressed areas. Other factors affecting market growth in the AMEA include a lack of understanding about sophisticated technology, low spending capacity, lack of access to healthcare facilities, and cancer detection at a later stage.

Market Segmentations and Scope of the Study:

The Cancer Tumor Profiling market is segmented on the basis of technique, technology, application and geography. On the basis of technique, the market is divided into genomics, proteomics, metabolomics, and epigenomics. On the basis of technology, the market is classified into immunoassay, NGS, insitu hybridization, mass spectrometry, pcr, microarray and others. On the basis of insitu hybridization, the market is further sub segmented into FISH and CISH. On the basis of application, the market is categorized into research applications and clinical applications. On the basis of research applications, the market is further sub segmented into biomarker discovery and personalized cancer medicine. On the basis of clinical application, the market is further classified into oncological diagnostics, prognostics, monitoring and treatment, screening. Geographic breakdown and analysis of each of the aforesaid segments includes regions comprising of North America, Europe, Asia-Pacific, and RoW.

Geographical Analysis

North America region is anticipated to hold the highest market share during the forecast period. This is due to the factors such as growing new product launches in countries like the United States and Canada, and increasing prevalence of patients suffering from cancer, advancements in technologies, and high consumer awareness. With a high number of companies active in cancer research and targeted drug delivery development, oncology biomarker testing is becoming more popular in the region. Furthermore, the high cost of products in the United States, as well as the growing number of genome sequencing program, make it an appealing market. The US National Cancer Institute (NCI) established the Cancer Genome Atlas program, which has sequenced more than 20,000 primary cancer samples from 33 cancer types.

However, the cancer profiling market, on the other hand, is predicted to grow at the fastest rate in Asia Pacific. This is due to an increase in cancer cases in the area. Countries like India, China, and South Korea are demonstrating remarkable economic growth and, as a result, improved healthcare infrastructure, which in turn is also drives the growth of the market in this region.

Competitive Landscape

The Cancer Tumor Profiling market comprising of various market players such as Lucence Health Inc., F. Hoffmann-La Roche Ltd, Caris Life Sciences, ACT Genomics Co., LTD, Thermo Fisher Scientific Inc., Strand Life Sciences, IMB Dx, Inc., Illumina, Inc., Guardant Health, QIAGEN, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics, Inc., NanoString, NeoGenomics Laboratories and Exact Sciences Corporation (Genomic Health, Inc.). These market players are adopting various joint venture strategies and planning expansion of business across various regions to maintain their dominance in the cancer tumor profiling market. For instance, in November 2021, Lucence in partnership with VA Palo Alto Healthcare System launched liquid biopsy screening study. The study examines the utilization of non-invasive liquid biopsy for high-risk patients together with imaging tools for lung cancer screening.

Also, in October 2021, Roche in collaboration with PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology developed an embedded image analysis workflow for pathologists. This can benefit cancer patients through more precise diagnosis, there by leading to targeted treatment.

KEY MARKET SEGMENTS

Cancer Tumor Profiling Market- by Technique

  • Genomics
  • Proteomics
  • Metabolomics
  • Epigenomics

Cancer Tumor Profiling Market- by Technology

  • Immunoassay
    • NGS
  • Insitu Hybridization
    • FISH
    • CISH
  • Mass Spectrometry
    • PCR
    • Microarray
    • Others

Cancer Tumor Profiling Market- by Application

  • Research applications
    • Biomarker Discovery
    • Personalized Cancer Medicine
  • Clinical applications
    • Oncological Diagnostics
    • Prognostics
    • Monitoring And Treatment
    • Screening

Cancer Tumor Profiling Market- by Geography

  • North America
    • U.S
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Rest of the Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Singapore
    • Australia
    • Indonesia
    • Vietnam
    • Res of the Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East
    • Isreal
    • UAE
    • Saudi Arabia
    • Rest of the Middle East
  • Africa
    • South Africa
    • Nigeria
    • Rest of Africa

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. WHO SHOULD READ THIS REPORT
  • 1.3. KEY MARKET SEGMENTS
  • 1.4. RESEARCH METHODOLOGY
    • 1.4.1 SECONDARY RESEARCH
    • 1.4.2 DATA ANALYSIS FRAMEWORK
    • 1.4.3 MARKET SIZE ESTIMATION
    • 1.4.4 FORECASTING
    • 1.4.5 PRIMARY RESEARCH AND DATA VALIDATION

2. CANCER/TUMOR PROFILING MARKET - EXECUTIVE SUMMARY

  • 2.1. MARKET SNAPSHOT, 2020 - 2030, MILLION USD

3. MARKET OVERVIEW

  • 3.1. MARKET DEFINITION AND SCOPE
  • 3.2. MARKET DYNAMICS
    • 3.2.1 DRIVERS
      • 3.2.1.1 Increasing Prevalence of Cancer Worldwide Anticipated to Propel the Market Growth
      • 3.2.1.2 Rise in Research and Development Activities and Increasing New Product Approvals to Boost the Market Growth
    • 3.2.2 RESTRAINTS
      • 3.2.2.1 High Cost of Cancer Profiling Tests to Hamper Growth of the Tumor Profiling Market
      • 3.2.2.2 Poor Reimbursement Policies and Lack of Access to Healthcare Infrastructure required for Cancer Profiling are Likely to Suppress the Market Growth
    • 3.2.3 OPPORTUNITIES
      • 3.2.3.1 Huge unmet need and economic development of the developing countries in Asia Pacific and MEA region leverages significant growth opportunities

4. COVID-19 ANALYSIS

  • 4.1. IMPACT OF COVID-19 ON CANCER OR TUMOR PROFILING MARKET

5. MARKET SHARE ANALYSIS

  • 5.1. MARKET SHARE ANALYSIS OF TOP GLOBAL CANCER/TUMOR PROFILING PROVIDERS, 2020
  • 5.2. MARKET SHARE ANALYSIS OF TOP NORTH AMERICA CANCER/TUMOR PROFILING PROVIDERS, 2020
  • 5.3. MARKET SHARE ANALYSIS OF TOP EUROPE CANCER/TUMOR PROFILING PROVIDERS, 2020
  • 5.4. MARKET SHARE ANALYSIS OF TOP APAC CANCER/TUMOR PROFILING PROVIDERS, 2020
  • 5.5. MARKET SHARE ANALYSIS OF TOP ROW CANCER/TUMOR PROFILING PROVIDERS, 2020

6. PREMIUM INSIGHTS

  • 6.1. PREVALENCE OF CANCER BY KEY COUNTRIES
  • 6.2. OVERVIEW OF CGP TECHNOLOGY VS HOTSPOT TECHNOLOGY
  • 6.3. COMPREHENSIVE GENOME PROFILING:
  • 6.4. CANCER HOT SPOT TESTING
  • 6.5. UPTAKE OF CGP VS HOTSPOT TECHNIQUE IN AMEA REGION
  • 6.6. EXISTING AND EMERGING TECHNOLOGIES OF CANCER/TUMOR PROFILING
  • 6.7. GENOTYPING
  • 6.8. NEXT GENERATION SEQUENCING
  • 6.9. EMERGING TECHNOLOGIES FOR CANCER PROFILING

7. GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE

  • 7.1. OVERVIEW
  • 7.2. GENOMIC
    • 7.2.1 GENOMIC MARKET, BY REGION
      • 7.2.1.1 North America Genomic Market, By Country
      • 7.2.1.2 Europe Genomic Market, By Country
      • 7.2.1.3 Asia-Pacific Genomic Market, By Country
      • 7.2.1.4 Latin America Genomic Market, By Country
      • 7.2.1.5 Middle East Genomic Market, By Country
      • 7.2.1.6 Africa Genomic Market, By Country
  • 7.3. PROTEOMIC
    • 7.3.1 PROTEOMIC MARKET, BY REGION
      • 7.3.1.1 North America Proteomic Market, By Country
      • 7.3.1.2 Europe Proteomic Market, By Country
      • 7.3.1.3 Asia-Pacific Proteomic Market, By Country
      • 7.3.1.4 Latin America Proteomic Market, By Country
      • 7.3.1.5 Middle East Proteomic Market, By Country
      • 7.3.1.6 Africa Proteomic Market, By Country
  • 7.4. METABOLOMICS
    • 7.4.1 METABOLOMICS MARKET, BY REGION
      • 7.4.1.1 North America Metabolomics Market, By Country
      • 7.4.1.2 Europe Metabolomics Market, By Country
      • 7.4.1.3 Asia-Pacific Metabolomics Market, By Country
      • 7.4.1.4 Latin America Metabolomics Market, By Country
      • 7.4.1.5 Middle East Metabolomics Market, By Country
      • 7.4.1.6 Africa Metabolomics Market, By Country
  • 7.5. EPIGENETICS
    • 7.5.1 EPIGENETICS MARKET, BY REGION
      • 7.5.1.1 North America Epigenetics Market, By Country
      • 7.5.1.2 Europe Epigenetics Market, By Country
      • 7.5.1.3 Asia-Pacific Epigenetics Market, By Country
      • 7.5.1.4 Latin America Epigenetics Market, By Country
      • 7.5.1.5 Middle East Epigenetics Market, By Country
      • 7.5.1.6 Africa Epigenetics Market, By Country

8. GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

  • 8.1. OVERVIEW
  • 8.2. IMMUNOASSAY
    • 8.2.1 IMMUNOASSAY MARKET, BY REGION
      • 8.2.1.1 North America Immunoassay Market, By Country
      • 8.2.1.2 Europe Immunoassay Market, By Country
      • 8.2.1.3 Asia-Pacific Immunoassay Market, By Country
      • 8.2.1.4 Latin America Immunoassay Market, By Country
      • 8.2.1.5 Middle East Immunoassay Market, By Country
      • 8.2.1.6 Africa Immunoassay Market, By Country
  • 8.3. NGS
    • 8.3.1 NGS MARKET, BY REGION
      • 8.3.1.1 North America NGS Market, By Country
      • 8.3.1.2 Europe NGS Market, By Country
      • 8.3.1.3 Asia-Pacific NGS Market, By Country
      • 8.3.1.4 Latin America NGS Market, By Country
      • 8.3.1.5 Middle East NGS Market, By Country
      • 8.3.1.6 Africa NGS Market, By Country
  • 8.4. INSITU HYBRIDIZATION
    • 8.4.1 GLOBAL INSITU HYBRIDIZATION MARKET, BY TECHNOLOGY
      • 8.4.1.1 FISH Market, By Region
        • 8.4.1.1.1 North America FISH Market, By Country
        • 8.4.1.1.2 Europe FISH Market, By Country
        • 8.4.1.1.3 Asia-Pacific FISH Market, By Country
        • 8.4.1.1.4 Latin America FISH Market, By Country
        • 8.4.1.1.5 Middle East FISH Market, By Country
        • 8.4.1.1.6 Africa FISH Market, By Country
      • 8.4.1.2 CISH Market, By Region
        • 8.4.1.2.1 North America CISH Market, By Country
        • 8.4.1.2.2 Europe CISH Market, By Country
        • 8.4.1.2.3 Asia-Pacific CISH Market, By Country
        • 8.4.1.2.4 Latin America CISH Market, By Country
        • 8.4.1.2.5 Middle East CISH Market, By Country
        • 8.4.1.2.6 Africa CISH Market, By Country
    • 8.4.2 INSITU HYBRIDIZATION MARKET, BY REGION
      • 8.4.2.1 North America Insitu Hybridization Market, By Country
      • 8.4.2.2 Europe Insitu Hybridization Market, By Country
      • 8.4.2.3 Asia-Pacific Insitu Hybridization Market, By Country
      • 8.4.2.4 Latin America Insitu Hybridization Market, By Country
      • 8.4.2.5 Middle East Insitu Hybridization Market, By Country
      • 8.4.2.6 Africa Insitu Hybridization Market, By Country
  • 8.5. MASS SPECTROMETRY
    • 8.5.1 MASS SPECTROMETRY MARKET, BY REGION
      • 8.5.1.1 North America Mass Spectrometry Market, By Country
      • 8.5.1.2 Europe Mass Spectrometry Market, By Country
      • 8.5.1.3 Asia-Pacific Mass Spectrometry Market, By Country
      • 8.5.1.4 Latin America Mass Spectrometry Market, By Country
      • 8.5.1.5 Middle East Mass Spectrometry Market, By Country
      • 8.5.1.6 Africa Mass Spectrometry Market, By Country
  • 8.6. PCR
    • 8.6.1 PCR MARKET, BY REGION
      • 8.6.1.1 North America PCR Market, By Country
      • 8.6.1.2 Europe PCR Market, By Country
      • 8.6.1.3 Asia-Pacific PCR Market, By Country
      • 8.6.1.4 Latin America PCR Market, By Country
      • 8.6.1.5 Middle East PCR Market, By Country
      • 8.6.1.6 Africa PCR Market, By Country
  • 8.7. MICROARRAY
    • 8.7.1 MICROARRAY MARKET, BY REGION
      • 8.7.1.1 North America Microarray Market, By Country
      • 8.7.1.2 Europe Microarray Market, By Country
      • 8.7.1.3 Asia-Pacific Microarray Market, By Country
      • 8.7.1.4 Latin America Microarray Market, By Country
      • 8.7.1.5 Middle East Microarray Market, By Country
      • 8.7.1.6 Africa Microarray Market, By Country
  • 8.8. OTHERS
    • 8.8.1 OTHERS MARKET, BY REGION
      • 8.8.1.1 North America Others Market, By Country
      • 8.8.1.2 Europe Others Market, By Country
      • 8.8.1.3 Asia-Pacific Others Market, By Country
      • 8.8.1.4 Latin America Others Market, By Country
      • 8.8.1.5 Middle East Others Market, By Country
      • 8.8.1.6 Africa Others Market, By Country

9. GLOBAL CANCER/TUMOR PROFILING MARKET, BY APPLICATION

  • 9.1. OVERVIEW
  • 9.2. RESEARCH APPLICATION
    • 9.2.1 GLOBAL RESEARCH APPLICATION MARKET, BY APPLICATION
      • 9.2.1.1 Biomarker Discovery Market, By Region
        • 9.2.1.1.1 North America Biomarker Discovery Market, By Country
        • 9.2.1.1.2 Europe Biomarker Discovery Market, By Country
        • 9.2.1.1.3 Asia-Pacific Biomarker Discovery Market, By Country
        • 9.2.1.1.4 Latin America Biomarker Discovery Market, By Country
        • 9.2.1.1.5 Middle East Biomarker Discovery Market, By Country
        • 9.2.1.1.6 Africa Biomarker Discovery Market, By Country
      • 9.2.1.2 Personalized Cancer Medicine Market, By Region
        • 9.2.1.2.1 North America Personalized Cancer Medicine Market, By Country
        • 9.2.1.2.2 Europe Personalized Cancer Medicine Market, By Country
        • 9.2.1.2.3 Asia-Pacific Personalized Cancer Medicine Market, By Country
        • 9.2.1.2.4 Latin America Personalized Cancer Medicine Market, By Country
        • 9.2.1.2.5 Middle East Personalized Cancer Medicine Market, By Country
        • 9.2.1.2.6 Africa Personalized Cancer Medicine Market, By Country
    • 9.2.2 RESEARCH APPLICATION MARKET, BY REGION
      • 9.2.2.1 North America Research Application Market, By Country
      • 9.2.2.2 Europe Research Application Market, By Country
      • 9.2.2.3 Asia-Pacific Research Application Market, By Country
      • 9.2.2.4 Latin America Research Application Market, By Country
      • 9.2.2.5 Middle East Research Application Market, By Country
      • 9.2.2.6 Africa Research Application Market, By Country
  • 9.3. CLINICAL APPLICATION
    • 9.3.1 GLOBAL CLINICAL APPLICATION MARKET, BY APPLICATION
      • 9.3.1.1 Oncological Diagnostics Market, By Region
        • 9.3.1.1.1 North America Oncological Diagnostics Market, By Country
        • 9.3.1.1.2 Europe Oncological Diagnostics Market, By Country
        • 9.3.1.1.3 Asia-Pacific Oncological Diagnostics Market, By Country
        • 9.3.1.1.4 Latin America Oncological Diagnostics Market, By Country
        • 9.3.1.1.5 Middle East Oncological Diagnostics Market, By Country
        • 9.3.1.1.6 Africa Oncological Diagnostics Market, By Country
      • 9.3.1.2 Prognostics Market, By Region
        • 9.3.1.2.1 North America Prognostics Market, By Country
        • 9.3.1.2.2 Europe Prognostics Market, By Country
        • 9.3.1.2.3 Asia-Pacific Prognostics Market, By Country
        • 9.3.1.2.4 Latin America Prognostics Market, By Country
        • 9.3.1.2.5 Middle East Prognostics Market, By Country
        • 9.3.1.2.6 Africa Prognostics Market, By Country
      • 9.3.1.3 Monitoring And Treatment Market, By Region
        • 9.3.1.3.1 North America Monitoring And Treatment Market, By Country
        • 9.3.1.3.2 Europe Monitoring And Treatment Market, By Country
        • 9.3.1.3.3 Asia-Pacific Monitoring And Treatment Market, By Country
        • 9.3.1.3.4 Latin America Monitoring And Treatment Market, By Country
        • 9.3.1.3.5 Middle East Monitoring And Treatment Market, By Country
        • 9.3.1.3.6 Africa Monitoring And Treatment Market, By Country
      • 9.3.1.4 Screening Market, By Region
        • 9.3.1.4.1 North America Screening Market, By Country
        • 9.3.1.4.2 Europe Screening Market, By Country
        • 9.3.1.4.3 Asia-Pacific Screening Market, By Country
        • 9.3.1.4.4 Latin America Screening Market, By Country
        • 9.3.1.4.5 Middle East Screening Market, By Country
        • 9.3.1.4.6 Africa Screening Market, By Country
    • 9.3.2 CLINICAL APPLICATION MARKET, BY REGION
      • 9.3.2.1 North America Clinical Application Market, By Country
      • 9.3.2.2 Europe Clinical Application Market, By Country
      • 9.3.2.3 Asia-Pacific Clinical Application Market, By Country
      • 9.3.2.4 Latin America Clinical Application Market, By Country
      • 9.3.2.5 Middle East Clinical Application Market, By Country
      • 9.3.2.6 Africa Clinical Application Market, By Country

10. GLOBAL CANCER/TUMOR PROFILING MARKET, BY REGION

  • 10.1. OVERVIEW
  • 10.2. NORTH AMERICA
    • 10.2.1 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
    • 10.2.2 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
      • 10.2.2.1 North America Insitu Hybridization Market, By Technology
    • 10.2.3 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION
      • 10.2.3.1 North America Research Application Market, By Application
      • 10.2.3.2 North America Clinical Application Market, By Application
    • 10.2.4 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY COUNTRY
      • 10.2.4.1 U.S.
        • 10.2.4.1.1 U.S. CANCER/TUMOR Profiling Market, By Technique
        • 10.2.4.1.2 U.S. CANCER/TUMOR Profiling Market, By Technology
        • 10.2.4.1.2.1. U.S. Insitu Hybridization Market, By Technology
        • 10.2.4.1.3 U.S. CANCER/TUMOR Profiling Market, By Application
        • 10.2.4.1.3.1. U.S. Research Application Market, By Application
        • 10.2.4.1.3.2. U.S. Clinical Application Market, By Application
      • 10.2.4.2 Canada
        • 10.2.4.2.1 Canada CANCER/TUMOR Profiling Market, By Technique
        • 10.2.4.2.2 Canada CANCER/TUMOR Profiling Market, By Technology
        • 10.2.4.2.2.1. Canada Insitu Hybridization Market, By Technology
        • 10.2.4.2.3 Canada CANCER/TUMOR Profiling Market, By Application
        • 10.2.4.2.3.1. Canada Research Application Market, By Application
        • 10.2.4.2.3.2. Canada Clinical Application Market, By Application
  • 10.3. EUROPE
    • 10.3.1 EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
    • 10.3.2 EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
      • 10.3.2.1 Europe Insitu Hybridization Market, By Technology
    • 10.3.3 EUROPE CANCER/TUMOR PROFILING MARKET, BY APPLICATION
      • 10.3.3.1 Europe Research Application Market, By Application
      • 10.3.3.2 Europe Clinical Application Market, By Application
    • 10.3.4 EUROPE CANCER/TUMOR PROFILING MARKET, BY COUNTRY
      • 10.3.4.1 Germany
        • 10.3.4.1.1 Germany CANCER/TUMOR Profiling Market, By Technique
        • 10.3.4.1.2 Germany CANCER/TUMOR Profiling Market, By Technology
        • 10.3.4.1.2.1. Germany Insitu Hybridization Market, By Technology
        • 10.3.4.1.3 Germany CANCER/TUMOR Profiling Market, By Application
        • 10.3.4.1.3.1. Germany Research Application Market, By Application
        • 10.3.4.1.3.2. Germany Clinical Application Market, By Application
      • 10.3.4.2 France
        • 10.3.4.2.1 France CANCER/TUMOR Profiling Market, By Technique
        • 10.3.4.2.2 France CANCER/TUMOR Profiling Market, By Technology
        • 10.3.4.2.2.1. France Insitu Hybridization Market, By Technology
        • 10.3.4.2.3 France CANCER/TUMOR Profiling Market, By Application
        • 10.3.4.2.3.1. France Research Application Market, By Application
        • 10.3.4.2.3.2. France Clinical Application Market, By Application
      • 10.3.4.3 UK
        • 10.3.4.3.1 UK CANCER/TUMOR Profiling Market, By Technique
        • 10.3.4.3.2 UK CANCER/TUMOR Profiling Market, By Technology
        • 10.3.4.3.2.1. UK Insitu Hybridization Market, By Technology
        • 10.3.4.3.3 UK CANCER/TUMOR Profiling Market, By Application
        • 10.3.4.3.3.1. UK Research Application Market, By Application
        • 10.3.4.3.3.2. UK Clinical Application Market, By Application
      • 10.3.4.4 Spain
        • 10.3.4.4.1 Spain CANCER/TUMOR Profiling Market, By Technique
        • 10.3.4.4.2 Spain CANCER/TUMOR Profiling Market, By Technology
        • 10.3.4.4.2.1. Spain Insitu Hybridization Market, By Technology
        • 10.3.4.4.3 Spain CANCER/TUMOR Profiling Market, By Application
        • 10.3.4.4.3.1. Spain Research Application Market, By Application
        • 10.3.4.4.3.2. Spain Clinical Application Market, By Application
      • 10.3.4.5 Italy
        • 10.3.4.5.1 Italy CANCER/TUMOR Profiling Market, By Technique
        • 10.3.4.5.2 Italy CANCER/TUMOR Profiling Market, By Technology
        • 10.3.4.5.2.1. Italy Insitu Hybridization Market, By Technology
        • 10.3.4.5.3 Italy CANCER/TUMOR Profiling Market, By Application
        • 10.3.4.5.3.1. Italy Research Application Market, By Application
        • 10.3.4.5.3.2. Italy Clinical Application Market, By Application
      • 10.3.4.6 Rest of the Europe
        • 10.3.4.6.1 Rest of the Europe CANCER/TUMOR Profiling Market, By Technique
        • 10.3.4.6.2 Rest of the Europe CANCER/TUMOR Profiling Market, By Technology
        • 10.3.4.6.2.1. Rest of the Europe Insitu Hybridization Market, By Technology
        • 10.3.4.6.3 Rest of the Europe CANCER/TUMOR Profiling Market, By Application
        • 10.3.4.6.3.1. Rest of the Europe Research Application Market, By Application
        • 10.3.4.6.3.2. Rest of the Europe Clinical Application Market, By Application
  • 10.4. ASIA-PACIFIC
    • 10.4.1 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
    • 10.4.2 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
      • 10.4.2.1 Asia-Pacific Insitu Hybridization Market, By Technology
    • 10.4.3 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY APPLICATION
      • 10.4.3.1 Asia-Pacific Research Application Market, By Application
      • 10.4.3.2 Asia-Pacific Clinical Application Market, By Application
    • 10.4.4 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY COUNTRY
      • 10.4.4.1 China
        • 10.4.4.1.1 China CANCER/TUMOR Profiling Market, By Technique
        • 10.4.4.1.2 China CANCER/TUMOR Profiling Market, By Technology
        • 10.4.4.1.2.1. China Insitu Hybridization Market, By Technology
        • 10.4.4.1.3 China CANCER/TUMOR Profiling Market, By Application
        • 10.4.4.1.3.1. China Research Application Market, By Application
        • 10.4.4.1.3.2. China Clinical Application Market, By Application
      • 10.4.4.2 India
        • 10.4.4.2.1 India CANCER/TUMOR Profiling Market, By Technique
        • 10.4.4.2.2 India CANCER/TUMOR Profiling Market, By Technology
        • 10.4.4.2.2.1. India Insitu Hybridization Market, By Technology
        • 10.4.4.2.3 India CANCER/TUMOR Profiling Market, By Application
        • 10.4.4.2.3.1. India Research Application Market, By Application
        • 10.4.4.2.3.2. India Clinical Application Market, By Application
      • 10.4.4.3 Japan
        • 10.4.4.3.1 Japan CANCER/TUMOR Profiling Market, By Technique
        • 10.4.4.3.2 Japan CANCER/TUMOR Profiling Market, By Technology
        • 10.4.4.3.2.1. Japan Insitu Hybridization Market, By Technology
        • 10.4.4.3.3 Japan CANCER/TUMOR Profiling Market, By Application
        • 10.4.4.3.3.1. Japan Research Application Market, By Application
        • 10.4.4.3.3.2. Japan Clinical Application Market, By Application
      • 10.4.4.4 South Korea
        • 10.4.4.4.1 South Korea CANCER/TUMOR Profiling Market, By Technique
        • 10.4.4.4.2 South Korea CANCER/TUMOR Profiling Market, By Technology
        • 10.4.4.4.2.1. South Korea Insitu Hybridization Market, By Technology
        • 10.4.4.4.3 South Korea CANCER/TUMOR Profiling Market, By Application
        • 10.4.4.4.3.1. South Korea Research Application Market, By Application
        • 10.4.4.4.3.2. South Korea Clinical Application Market, By Application
      • 10.4.4.5 Singapore
        • 10.4.4.5.1 Singapore CANCER/TUMOR Profiling Market, By Technique
        • 10.4.4.5.2 Singapore CANCER/TUMOR Profiling Market, By Technology
        • 10.4.4.5.2.1. Singapore Insitu Hybridization Market, By Technology
        • 10.4.4.5.3 Singapore CANCER/TUMOR Profiling Market, By Application
        • 10.4.4.5.3.1. Singapore Research Application Market, By Application
        • 10.4.4.5.3.2. Singapore Clinical Application Market, By Application
      • 10.4.4.6 Australia
        • 10.4.4.6.1 Australia CANCER/TUMOR Profiling Market, By Technique
        • 10.4.4.6.2 Australia CANCER/TUMOR Profiling Market, By Technology
        • 10.4.4.6.2.1. Australia Insitu Hybridization Market, By Technology
        • 10.4.4.6.3 Australia CANCER/TUMOR Profiling Market, By Application
        • 10.4.4.6.3.1. Australia Research Application Market, By Application
        • 10.4.4.6.3.2. Australia Clinical Application Market, By Application
      • 10.4.4.7 Indonesia
        • 10.4.4.7.1 Indonesia CANCER/TUMOR Profiling Market, By Technique
        • 10.4.4.7.2 Indonesia CANCER/TUMOR Profiling Market, By Technology
        • 10.4.4.7.2.1. Indonesia Insitu Hybridization Market, By Technology
        • 10.4.4.7.3 Indonesia CANCER/TUMOR Profiling Market, By Application
        • 10.4.4.7.3.1. Indonesia Research Application Market, By Application
        • 10.4.4.7.3.2. Indonesia Clinical Application Market, By Application
      • 10.4.4.8 Vietnam
        • 10.4.4.8.1 Vietnam CANCER/TUMOR Profiling Market, By Technique
        • 10.4.4.8.2 Vietnam CANCER/TUMOR Profiling Market, By Technology
        • 10.4.4.8.2.1. Vietnam Insitu Hybridization Market, By Technology
        • 10.4.4.8.3 Vietnam CANCER/TUMOR Profiling Market, By Application
        • 10.4.4.8.3.1. Vietnam Research Application Market, By Application
        • 10.4.4.8.3.2. Vietnam Clinical Application Market, By Application
      • 10.4.4.9 Res of the Asia Pacific
        • 10.4.4.9.1 Res of the Asia Pacific CANCER/TUMOR Profiling Market, By Technique
        • 10.4.4.9.2 Res of the Asia Pacific CANCER/TUMOR Profiling Market, By Technology
        • 10.4.4.9.2.1. Res of the Asia Pacific Insitu Hybridization Market, By Technology
        • 10.4.4.9.3 Res of the Asia Pacific CANCER/TUMOR Profiling Market, By Application
        • 10.4.4.9.3.1. Res of the Asia Pacific Research Application Market, By Application
        • 10.4.4.9.3.2. Res of the Asia Pacific Clinical Application Market, By Application
  • 10.5. LATIN AMERICA
    • 10.5.1 LATIN AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
    • 10.5.2 LATIN AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
      • 10.5.2.1 Latin America Insitu Hybridization Market, By Technology
    • 10.5.3 LATIN AMERICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION
      • 10.5.3.1 Latin America Research Application Market, By Application
      • 10.5.3.2 Latin America Clinical Application Market, By Application
    • 10.5.4 LATIN AMERICA CANCER/TUMOR PROFILING MARKET, BY COUNTRY
      • 10.5.4.1 Brazil
        • 10.5.4.1.1 Brazil CANCER/TUMOR Profiling Market, By Technique
        • 10.5.4.1.2 Brazil CANCER/TUMOR Profiling Market, By Technology
        • 10.5.4.1.2.1. Brazil Insitu Hybridization Market, By Technology
        • 10.5.4.1.3 Brazil CANCER/TUMOR Profiling Market, By Application
        • 10.5.4.1.3.1. Brazil Research Application Market, By Application
        • 10.5.4.1.3.2. Brazil Clinical Application Market, By Application
      • 10.5.4.2 Mexico
        • 10.5.4.2.1 Mexico CANCER/TUMOR Profiling Market, By Technique
        • 10.5.4.2.2 Mexico CANCER/TUMOR Profiling Market, By Technology
        • 10.5.4.2.2.1. Mexico Insitu Hybridization Market, By Technology
        • 10.5.4.2.3 Mexico CANCER/TUMOR Profiling Market, By Application
        • 10.5.4.2.3.1. Mexico Research Application Market, By Application
        • 10.5.4.2.3.2. Mexico Clinical Application Market, By Application
      • 10.5.4.3 Rest of LATAM
        • 10.5.4.3.1 Rest of LATAM CANCER/TUMOR Profiling Market, By Technique
        • 10.5.4.3.2 Rest of LATAM CANCER/TUMOR Profiling Market, By Technology
        • 10.5.4.3.2.1. Rest of LATAM Insitu Hybridization Market, By Technology
        • 10.5.4.3.3 Rest of LATAM CANCER/TUMOR Profiling Market, By Application
        • 10.5.4.3.3.1. Rest of LATAM Research Application Market, By Application
        • 10.5.4.3.3.2. Rest of LATAM Clinical Application Market, By Application
  • 10.6. MIDDLE EAST
    • 10.6.1 MIDDLE EAST CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
    • 10.6.2 MIDDLE EAST CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
      • 10.6.2.1 Middle East Insitu Hybridization Market, By Technology
    • 10.6.3 MIDDLE EAST CANCER/TUMOR PROFILING MARKET, BY APPLICATION
      • 10.6.3.1 Middle East Research Application Market, By Application
      • 10.6.3.2 Middle East Clinical Application Market, By Application
    • 10.6.4 MIDDLE EAST CANCER/TUMOR PROFILING MARKET, BY COUNTRY
      • 10.6.4.1 Isreal
        • 10.6.4.1.1 Isreal CANCER/TUMOR Profiling Market, By Technique
        • 10.6.4.1.2 Isreal CANCER/TUMOR Profiling Market, By Technology
        • 10.6.4.1.2.1. Isreal Insitu Hybridization Market, By Technology
        • 10.6.4.1.3 Isreal CANCER/TUMOR Profiling Market, By Application
        • 10.6.4.1.3.1. Isreal Research Application Market, By Application
        • 10.6.4.1.3.2. Isreal Clinical Application Market, By Application
      • 10.6.4.2 UAE
        • 10.6.4.2.1 UAE CANCER/TUMOR Profiling Market, By Technique
        • 10.6.4.2.2 UAE CANCER/TUMOR Profiling Market, By Technology
        • 10.6.4.2.2.1. UAE Insitu Hybridization Market, By Technology
        • 10.6.4.2.3 UAE CANCER/TUMOR Profiling Market, By Application
        • 10.6.4.2.3.1. UAE Research Application Market, By Application
        • 10.6.4.2.3.2. UAE Clinical Application Market, By Application
      • 10.6.4.3 Saudi Arabia
        • 10.6.4.3.1 Saudi Arabia CANCER/TUMOR Profiling Market, By Technique
        • 10.6.4.3.2 Saudi Arabia CANCER/TUMOR Profiling Market, By Technology
        • 10.6.4.3.2.1. Saudi Arabia Insitu Hybridization Market, By Technology
        • 10.6.4.3.3 Saudi Arabia CANCER/TUMOR Profiling Market, By Application
        • 10.6.4.3.3.1. Saudi Arabia Research Application Market, By Application
        • 10.6.4.3.3.2. Saudi Arabia Clinical Application Market, By Application
      • 10.6.4.4 Rest of the Middle East
        • 10.6.4.4.1 Rest of the Middle East CANCER/TUMOR Profiling Market, By Technique
        • 10.6.4.4.2 Rest of the Middle East CANCER/TUMOR Profiling Market, By Technology
        • 10.6.4.4.2.1. Rest of the Middle East Insitu Hybridization Market, By Technology
        • 10.6.4.4.3 Rest of the Middle East CANCER/TUMOR Profiling Market, By Application
        • 10.6.4.4.3.1. Rest of the Middle East Research Application Market, By Application
        • 10.6.4.4.3.2. Rest of the Middle East Clinical Application Market, By Application
  • 10.7. AFRICA
    • 10.7.1 AFRICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
    • 10.7.2 AFRICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
      • 10.7.2.1 Africa Insitu Hybridization Market, By Technology
    • 10.7.3 AFRICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION
      • 10.7.3.1 Africa Research Application Market, By Application
      • 10.7.3.2 Africa Clinical Application Market, By Application
    • 10.7.4 AFRICA CANCER/TUMOR PROFILING MARKET, BY COUNTRY
      • 10.7.4.1 South Africa
        • 10.7.4.1.1 South Africa CANCER/TUMOR Profiling Market, By Technique
        • 10.7.4.1.2 South Africa CANCER/TUMOR Profiling Market, By Technology
        • 10.7.4.1.2.1. South Africa Insitu Hybridization Market, By Technology
        • 10.7.4.1.3 South Africa CANCER/TUMOR Profiling Market, By Application
        • 10.7.4.1.3.1. South Africa Research Application Market, By Application
        • 10.7.4.1.3.2. South Africa Clinical Application Market, By Application
      • 10.7.4.2 Nigeria
        • 10.7.4.2.1 Nigeria CANCER/TUMOR Profiling Market, By Technique
        • 10.7.4.2.2 Nigeria CANCER/TUMOR Profiling Market, By Technology
        • 10.7.4.2.2.1. Nigeria Insitu Hybridization Market, By Technology
        • 10.7.4.2.3 Nigeria CANCER/TUMOR Profiling Market, By Application
        • 10.7.4.2.3.1. Nigeria Research Application Market, By Application
        • 10.7.4.2.3.2. Nigeria Clinical Application Market, By Application
      • 10.7.4.3 Rest of Africa
        • 10.7.4.3.1 Rest of Africa CANCER/TUMOR Profiling Market, By Technique
        • 10.7.4.3.2 Rest of Africa CANCER/TUMOR Profiling Market, By Technology
        • 10.7.4.3.2.1. Rest of Africa Insitu Hybridization Market, By Technology
        • 10.7.4.3.3 Rest of Africa CANCER/TUMOR Profiling Market, By Application
        • 10.7.4.3.3.1. Rest of Africa Research Application Market, By Application
        • 10.7.4.3.3.2. Rest of Africa Clinical Application Market, By Application

11. COMPANY PROFILES

  • 11.1. LUCENCE HEALTH INC
    • 11.1.1 COMPANY OVERVIEW
    • 11.1.2 COMPANY SNAPSHOT
    • 11.1.3 PRODUCT PORTFOLIO
    • 11.1.4 KEY STRATEGIC MOVES & DEVELOPMENTS
    • 11.1.5 SWOT ANALYSIS
  • 11.2. F. HOFFMANN-LA ROCHE LTD
    • 11.2.1 COMPANY OVERVIEW
    • 11.2.2 COMPANY SNAPSHOT
    • 11.2.3 OPERATING BUSINESS SEGMENTS
    • 11.2.4 PRODUCT PORTFOLIO
    • 11.2.5 BUSINESS PERFORMANCE
    • 11.2.6 SALES BY BUSINESS SEGMENT
    • 11.2.7 SALES BY GEOGRAPHIC SEGMENT
    • 11.2.8 KEY STRATEGIC MOVES & DEVELOPMENTS
    • 11.2.9 SWOT ANALYSIS
  • 11.3. CARIS LIFE SCIENCES
    • 11.3.1 COMPANY OVERVIEW
    • 11.3.2 COMPANY SNAPSHOT
    • 11.3.3 PRODUCT PORTFOLIO
    • 11.3.4 KEY STRATEGIC MOVES & DEVELOPMENTS
    • 11.3.5 SWOT ANALYSIS
  • 11.4. ACT GENOMICS CO., LTD
    • 11.4.1 COMPANY OVERVIEW
    • 11.4.2 COMPANY SNAPSHOT
    • 11.4.3 PRODUCT PORTFOLIO
    • 11.4.4 KEY STRATEGIC MOVES & DEVELOPMENTS
    • 11.4.5 SWOT ANALYSIS
  • 11.5. THERMO FISHER SCIENTIFIC INC.
    • 11.5.1 COMPANY OVERVIEW
    • 11.5.2 COMPANY SNAPSHOT
    • 11.5.3 OPERATING BUSINESS SEGMENTS
    • 11.5.4 PRODUCT PORTFOLIO
    • 11.5.5 BUSINESS PERFORMANCE
    • 11.5.6 SALES BY BUSINESS SEGMENT
    • 11.5.7 SALES BY GEOGRAPHIC SEGMENT
    • 11.5.8 KEY STRATEGIC MOVES & DEVELOPMENTS
    • 11.5.9 SWOT ANALYSIS
  • 11.6. STRAND LIFE SCIENCES
    • 11.6.1 COMPANY OVERVIEW
    • 11.6.2 COMPANY SNAPSHOT
    • 11.6.3 PRODUCT PORTFOLIO
    • 11.6.4 SWOT ANALYSIS
  • 11.7. IMB DX, INC.
    • 11.7.1 COMPANY OVERVIEW
    • 11.7.2 COMPANY SNAPSHOT
    • 11.7.3 PRODUCT PORTFOLIO
    • 11.7.4 SWOT ANALYSIS
  • 11.8. ILLUMINA, INC.
    • 11.8.1 COMPANY OVERVIEW
    • 11.8.2 COMPANY SNAPSHOT
    • 11.8.3 PRODUCT PORTFOLIO
    • 11.8.4 BUSINESS PERFORMANCE
    • 11.8.5 SALES BY GEOGRAPHIC SEGMENT
    • 11.8.6 KEY STRATEGIC MOVES & DEVELOPMENTS
    • 11.8.7 SWOT ANALYSIS
  • 11.9. GUARDANT HEALTH
    • 11.9.1 COMPANY OVERVIEW
    • 11.9.2 COMPANY SNAPSHOT
    • 11.9.3 PRODUCT PORTFOLIO
    • 11.9.4 BUSINESS PERFORMANCE
    • 11.9.5 SALES BY GEOGRAPHIC SEGMENT
    • 11.9.6 KEY STRATEGIC MOVES & DEVELOPMENTS
    • 11.9.7 SWOT ANALYSIS
  • 11.10. QIAGEN
    • 11.10.1 COMPANY OVERVIEW
    • 11.10.2 COMPANY SNAPSHOT
    • 11.10.3 PRODUCT PORTFOLIO
    • 11.10.4 BUSINESS PERFORMANCE
    • 11.10.5 SALES BY GEOGRAPHIC SEGMENT
    • 11.10.6 KEY STRATEGIC MOVES & DEVELOPMENTS
    • 11.10.7 SWOT ANALYSIS
  • 11.11. EXACT SCIENCES CORPORATION (GENOMIC HEALTH, INC.)
    • 11.11.1 COMPANY OVERVIEW
    • 11.11.2 COMPANY SNAPSHOT
    • 11.11.3 PRODUCT PORTFOLIO
    • 11.11.4 BUSINESS PERFORMANCE
    • 11.11.5 SALES BY GEOGRAPHIC SEGMENT
    • 11.11.6 KEY STRATEGIC MOVES & DEVELOPMENTS
    • 11.11.7 SWOT ANALYSIS
  • 11.12. NEOGENOMICS LABORATORIES
    • 11.12.1 COMPANY OVERVIEW
    • 11.12.2 COMPANY SNAPSHOT
    • 11.12.3 OPERATING BUSINESS SEGMENTS
    • 11.12.4 PRODUCT PORTFOLIO
    • 11.12.5 BUSINESS PERFORMANCE
    • 11.12.6 SALES BY BUSINESS SEGMENT
    • 11.12.7 KEY STRATEGIC MOVES & DEVELOPMENTS
    • 11.12.8 SWOT ANALYSIS
  • 11.13. NANOSTRING
    • 11.13.1 COMPANY OVERVIEW
    • 11.13.2 COMPANY SNAPSHOT
    • 11.13.3 PRODUCT PORTFOLIO
    • 11.13.4 BUSINESS PERFORMANCE
    • 11.13.5 SALES BY GEOGRAPHIC SEGMENT
    • 11.13.6 KEY STRATEGIC MOVES & DEVELOPMENTS
    • 11.13.7 SWOT ANALYSIS
  • 11.14. HTG MOLECULAR DIAGNOSTICS, INC.
    • 11.14.1 COMPANY OVERVIEW
    • 11.14.2 COMPANY SNAPSHOT
    • 11.14.3 PRODUCT PORTFOLIO
    • 11.14.4 BUSINESS PERFORMANCE
    • 11.14.5 SWOT ANALYSIS
  • 11.15. RIBOMED BIOTECHNOLOGIES INC
    • 11.15.1 COMPANY OVERVIEW
    • 11.15.2 COMPANY SNAPSHOT
    • 11.15.3 PRODUCT PORTFOLIO
    • 11.15.4 SWOT ANALYSIS